Korean J healthc assoc Infect Control Prev.  2022 Jun;27(1):51-58. 10.14192/kjicp.2022.27.1.51.

Microorganisms Isolated from Urine Cultures and Their Antimicrobial Susceptibility Patterns at a Commercial Laboratory during 2018-2020

• Kwak B
• Hong J
• Bae HG
• Park YS
• Lee MK
• Lee K
• Lee KR

• KMID: 2530826
• DOI: http://doi.org/10.14192/kjicp.2022.27.1.51

Abstract

Background
Antimicrobial resistance of bacterial pathogens that cause urinary tract infections is a leading concern in Korea. This study analyzed the urine culture results and antimicrobial susceptibility trend in different types of healthcare facilities including long-term care hospitals. The aim of the study was to derive relevant information for the empirical treatment of patients with antibiotics.
Methods
We analyzed the species and antimicrobial susceptibility of the isolates from urine cultures received at the Seoul Clinical Laboratories from 2018 to 2020. Organisms were identified using Microflex MALDI Biotyper (Bruker Daltonik GmbH, Germany). Antimicrobial susceptibility was tested using the Vitek 2 automated system (bioMérieux, France).
Results
The most frequently isolated organism was Escherichia coli. In general and small and medium sized hospitals, Enterococcus faecalis was the next most frequently isolated organism. In long term care hospitals (LTCH), Proteus mirabilis was the next most frequently isolated organism. A total of 37-70% of E. Coli, 51-76% of Klebsiella pneumoniae, and 52-85% of P. mirabilis strains were cefotaxime resistant. The incidence of fluoroquinolone-resistant isolates for the aforementioned strains was 48-86%, 51-83%, and 60-95% respectively. A total of 8-22% of isolates of K. pneumoniae were carbapenem-resistant. The incidence of carbapenem resistant K. pneumoniae in LTCH increased sharply from 8% in 2018 to 38-40% in 2020. The incidence of glycopeptide-resistant E. faecalis was 27-80%.
Conclusion
This study demonstrated that the use of fluroquinolones and b-lactam antibiotics recommended for empirical antibiotic therapy was limited considering the high prevalence of antibiotic resistant organism. Antimicrobial stewardship programs and infection control programs may also play an important role considering the high prevalence of antimicrobialresistant organisms especially in LTCH.

Keyword

Antimicrobial resistance; Long-term care hospital; Urine culture

Figure

• 

  Fig. 1 Antimicrobial resistance rate (%) of 6 microorganisms from 2018 to 2020 by year.

Reference

1. Bader MS, Loeb M, Leto D, Brooks AA. 2020; Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 132:234–50. DOI: 10.1080/00325481.2019.1680052. PMID: 31608743.

2. Kanjilal S, Oberst M, Boominathan S, Zhou H, Hooper DC, Sontag D. 2020; A decision algorithm to promote outpatient antimicrobial stewardship for uncomplicated urinary tract infection. Sci Transl Med. 12:eaay5067. DOI: 10.1126/scitranslmed.aay5067. PMID: 33148625.

3. Lee SJ. 2009; Current status of antimicrobial resistance among bacterial pathogens causing urinary tract infection in Korea. Korean J Urogenit Tract Infect Inflamm. 4:37–46.

4. Kang CI, Kim J, Park DW, Kim BN, Ha US, Lee SJ, et al. 2018; Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections. Infect Chemother. 50:67–100. DOI: 10.3947/ic.2018.50.1.67. PMID: 29637759. PMCID: PMC5895837.

5. Korea Disease Control. One health AMR website on antimicrobial resistance organism surveillance system. 2020 One health AMR report. https://www.kdca.go.kr/nohas/statistics/selectTestMethodCh9.do. (Updated on 30 June 2021).

6. Yonsei University College of Medicine. Yonsei University College of Medicine website on Research institute of bacterial resistance. Antimicrobial resistance newsletter. https://medicine.yonsei.ac.kr/medicine-en/research/bacterial-resistance-board.do. (Updated on on 26 February 2021).

7. Korea Disease Control. 2021. National antimicrobial resistance surveillance in Korea 2020 Annual Report. Korea Disease Control and Prevention Agency;Cheongju: p. 83–85.

8. CLSI. 2018. Performance standards for antimicrobial susceptibility testing. CLSI document M100. 28th ed. CLSI;Wayne: p. 29–54. DOI: 10.1016/s0196-4399(01)88009-0.

9. CLSI. 2019. Performance standards for antimicrobial susceptibility testing. CLSI document M100. 29th ed. CLSI;Wayne: p. 42–76. DOI: 10.1016/s0196-4399(01)88009-0.

10. CLSI. 2020. Performance standards for antimicrobial susceptibility testing. CLSI document M100. 30th ed. CLSI;Wayne: p. 31–59. DOI: 10.1016/s0196-4399(01)88009-0.

11. Schaffer JN, Pearson MM. 2015; Proteus mirabilis and urinary tract infections. Microbiol Spectr. 3:10.1128/microbiolspec.UTI-0017-2013. DOI: 10.1128/microbiolspec.UTI-0017-2013. PMID: 26542036. PMCID: PMC4638163.

12. Eure TR, Stone ND, Mungai EA, Bell JM, Thompson ND. 2021; Antibiotic-resistant pathogens associated with urinary tract infections in nursing homes: summary of data reported to the National Healthcare Safety Network Long-Term Care Facility Component, 2013-2017. Infect Control Hosp Epidemiol. 42:31–6. DOI: 10.1017/ice.2020.348. PMID: 32782037.

13. Ny S, Edquist P, Dumpis U, Gröndahl-Yli-Hannuksela K, Hermes J, Kling AM, et al. 2019; Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 17:25–34. DOI: 10.1016/j.jgar.2018.11.004. PMID: 30447337.

14. Karlowsky JA, Lagacé-Wiens PRS, Adam HJ, Baxter MR, Laing NM, Walkty AJ, et al. 2019; In vitro susceptibility of urinary Escherichia coli isolates to first- and second-line empirically prescribed oral antimicrobials: CANWARD surveillance study results for Canadian outpatients, 2007-2016. Int J Antimicrob Agents. 54:62–8. DOI: 10.1016/j.ijantimicag.2019.04.012. PMID: 31034938.

15. Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, et al. 2018; Antimicrobial susceptibility trends observed in urinary pathogens obtained from New York state. Open Forum Infect Dis. 5:ofy297. DOI: 10.1093/ofid/ofy297. PMID: 30539040. PMCID: PMC6284462.

16. Kim YA, Kim JJ, Kim H, Lee K. 2017; Community-onset extended-spectrum-β-lactamase-producing Escherichia coli sequence type 131 at two Korean community hospitals: the spread of multidrug-resistant E. coli to the community via healthcare facilities. Int J Infect Dis. 54:39–42. DOI: 10.1016/j.ijid.2016.11.010. PMID: 27865830.

17. Muller A, Gbaguidi-Haore H, Cholley P, Hocquet D, Sauget M, Bertrand X. 2021; Hospital-diagnosed infections with Escherichia coli clonal group ST131 are mostly acquired in the community. Sci Rep. 11:5702. DOI: 10.1038/s41598-021-85116-6. PMID: 33707589. PMCID: PMC7952690.

18. Kim D, Ahn JY, Lee CH, Jang SJ, Lee H, Yong D, et al. 2017; Increasing resistance to extended-spectrum cephalosporins, fluoroquinolone, and carbapenem in gram-negative bacilli and the emergence of carbapenem non-susceptibility in Klebsiella pneumoniae: analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) data from 2013 to 2015. Ann Lab Med. 37:231–9. DOI: 10.3343/alm.2017.37.3.231. PMID: 28224769. PMCID: PMC5339095.

19. Lee E, Lee S, Yoon S, Lee Y. 2021; Number of Cabapenem-resistant Enterobacteriaceae infections in the Republic of Korea (2018-2020). Public Health Wkly Rep. 14:2765–72.

20. Lee H, Yoon EJ, Kim D, Jeong SH, Won EJ, Shin JH, et al. 2018; Antimicrobial resistance of major clinical pathogens in South Korea, May 2016 to April 2017: first one-year report from Kor-GLASS. Euro Surveill. 23:1800047. DOI: 10.2807/1560-7917.ES.2018.23.42.1800047. PMID: 30352640. PMCID: PMC6199864.

21. Girlich D, Bonnin RA, Dortet L, Naas T. 2020; Genetics of acquired antibiotic resistance genes in Proteus spp. Front Microbiol. 11:256. DOI: 10.3389/fmicb.2020.00256. PMID: 32153540. PMCID: PMC7046756.

22. Yong D, Shin HB, Kim YK, Cho J, Lee WG, Ha GY, et al. 2014; Increase in the prevalence of carbapenem-resistant Acinetobacter isolates and ampicillin-resistant non-typhoidal Salmonella species in Korea: a KONSAR study conducted in 2011. Infect Chemother. 46:84–93. DOI: 10.3947/ic.2014.46.2.84. PMID: 25024870. PMCID: PMC4091365.

23. Zhang Y, Wang L, Zhou C, Lin Y, Liu S, Zeng W, et al. 2021; Unraveling mechanisms and epidemic characteristics of nitrofurantoin resistance in uropathogenic Enterococcus faecium clinical isolates. Infect Drug Resist. 14:1601–11. DOI: 10.2147/IDR.S301802. PMID: 33911884. PMCID: PMC8075312.

24. Nichol KA, Sill M, Laing NM, Johnson JL, Hoban DJ, Zhanel GG. 2006; Molecular epidemiology of urinary tract isolates of vancomycin-resistant Enterococcus faecium from North America. Int J Antimicrob Agents. 27:392–6. DOI: 10.1016/j.ijantimicag.2005.12.006. PMID: 16621463.

25. Choi JP, Cho EH, Lee SJ, Lee ST, Koo MS, Song YG. 2012; Influx of multidrug resistant, Gram-negative bacteria (MDRGNB) in a public hospital among elderly patients from long-term care facilities: a single-center pilot study. Arch Gerontol Geriatr. 54:e19–22. DOI: 10.1016/j.archger.2011.05.026. PMID: 21764147.

26. Choi MJ, Noh JY, Cheong HJ, Kim WJ, Kim MJ, Jang YS, et al. 2019; Spread of ceftriaxone non-susceptible pneumococci in South Korea: long-term care facilities as a potential reservoir. PLoS One. 14:e0210520. DOI: 10.1371/journal.pone.0210520. PMID: 30699137. PMCID: PMC6353129.

27. Kariya N, Sakon N, Komano J, Tomono K, Iso H. 2018; Current prevention and control of health care-associated infections in long-term care facilities for the elderly in Japan. J Infect Chemother. 24:347–52. DOI: 10.1016/j.jiac.2017.12.004. PMID: 29336918.

28. Yun SH, Gwon B, Hong HL, Lim HS, Lee KR, Jang I, et al. 2019; Antimicrobial resistance in bacterial isolates recovered from nursing hospitals between 2014 and 2017. Ann Clin Microbiol. 22:96–104. DOI: 10.5145/ACM.2019.22.4.96.